Apellis Pharmaceuticals (NASDAQ:APLS) Given New $32.00 Price Target at The Goldman Sachs Group
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective dropped by research analysts at The Goldman Sachs Group from $36.00 to $32.00 in a report issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target points to a potential upside of 27.74% from […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective dropped by research analysts at The Goldman Sachs Group from $36.00 to $32.00 in a report issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target points to a potential upside of 27.74% from […]
